Opinion|Videos|July 16, 2024
Economic Impacts and Pricing Strategies Surrounding Biosimilars
The panel discusses the economic impact biosimilars have across different patient types.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What economic impacts do biosimilars have in different delivery channels (inpatient, self-administered outpatient, outpatient infusion)?
- How do pricing strategies for biosimilars, such as the high and low list prices of adalimumab biosimilars, affect their market penetration and adoption?
- How do biosimilar pricing strategies affect patient access and affordability?
- Are there more effective pricing models that could be adopted?
- Are there certain customer subtypes that will want a rebate drive model vs. those want a rebate driven model vs. a WAC driven model?
Advertisement
Related to this article
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.
A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5